STOCK TITAN

Aurinia Pharmace Stock Price, News & Analysis

AUPH Nasdaq

Welcome to our dedicated page for Aurinia Pharmace news (Ticker: AUPH), a resource for investors and traders seeking the latest updates and insights on Aurinia Pharmace stock.

Aurinia Pharmaceuticals Inc. (AUPH) is a biopharmaceutical innovator developing therapies for autoimmune diseases with high unmet needs, including lupus nephritis. This page aggregates all company announcements, clinical trial updates, and regulatory developments.

Investors and healthcare professionals will find real-time access to earnings reports, partnership disclosures, and research milestones. Key coverage areas: FDA submissions, therapy commercialization progress, and scientific collaboration updates related to LUPKYNIS and pipeline candidates.

Bookmark this resource for verified information directly from corporate communications and curated third-party analysis. Check regularly for developments impacting Aurinia's position in autoimmune treatment markets.

Rhea-AI Summary

Lucien Selce, who owns 2.2% of Aurinia Pharmaceuticals (NASDAQ: AUPH), has urged shareholders to withhold support for CEO Peter Greenleaf and the current Board of Directors in the upcoming AGM on June 14, 2024. Selce accuses the Board of manipulating AGM dates to benefit from stock-based compensation and depriving certain shareholders of their voting rights. A leading proxy advisory firm, ISS, has also recommended withholding support for three directors and voting against proposed executive compensation. Selce highlights the stock's decline from $10.71 to $5.42 and suggests a new Board and CEO to rejuvenate Aurinia's performance and governance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
-
Rhea-AI Summary

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced its participation in the 2024 Jefferies Global Healthcare Conference in New York, scheduled from June 4-6, 2024.

The company's management will engage in one-on-one meetings with investors and deliver a presentation on June 5 from 8:00 to 8:25 AM Eastern Time.

A live webcast of the session will be accessible via the Investor section of Aurinia's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
none
-
Rhea-AI Summary

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced the cost-effectiveness of LUPKYNIS® (voclosporin) for treating lupus nephritis (LN) at the National Kidney Foundation Spring Clinical Meeting 2024. The updated analysis, consistent with a 2021 assessment, utilized the ICER AnalyticsTM LN model and found LUPKYNIS to be below the $150,000 willingness-to-pay threshold, costing $88,076 per QALY and $77,643 per evLYG for adults with active LN. For Black, Hispanic, and Latino patients, costs were $77,436 per QALY and $67,828 per evLYG. Additional data from the AURORA clinical program and the Enlight-LN registry highlighted the drug's sustained efficacy and reduced steroid use over three years. A propensity analysis indicated superior proteinuria reduction and decreased exposure to toxicities versus high-dose glucocorticoid regimens.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.59%
Tags
none
Rhea-AI Summary

Aurinia Pharmaceuticals Inc. presented data at the Congress of Clinical Rheumatology East 2024, reinforcing the safety and efficacy of LUPKYNIS in treating lupus nephritis. The studies showed that LUPKYNIS in combination with standard care reduced toxicities and proteinuria compared to conventional treatments. Black patients experienced improved outcomes with LUPKYNIS.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
none
-
Rhea-AI Summary

A shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has urged the Board of Directors to take action to enhance shareholder value. The shareholder, Lucien Selce, expressed concerns about the Company's current strategy, Board composition, and market penetration. He outlined the need for restructuring the Board, setting clear objectives for market penetration, and developing strategic partnerships to improve performance and shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
management
-
Rhea-AI Summary

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will attend the 2024 RBC Capital Markets Global Healthcare Conference in New York from May 14-15, 2024. Management will host one-on-one meetings with investors and participate in a fireside chat. A live webcast of the session will be available on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
none
Rhea-AI Summary

Aurinia Pharmaceuticals Inc. reported $50.3 million in total net revenue and $48.1 million in net product revenue for the first quarter of 2024, with a year-over-year growth of approximately 46% and 40% respectively. The company achieved significant milestones like FDA approval for LUPKYNIS and plans to reach positive free cash flows in Q2 2024. The 2024 net product revenue guidance is $200 to $220 million. Financially, total net revenue increased, operating expenses decreased, and the company maintained a strong liquidity position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
-
Rhea-AI Summary

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) reaffirms its commitment to raising awareness about lupus nephritis (LN) during Lupus Awareness Month. The company is engaging in various education initiatives to improve understanding, screening, and management of LN. Through partnerships and advocacy efforts, Aurinia aims to eliminate barriers to access, promote equity, and enhance health outcomes for individuals affected by LN.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.16%
Tags
none
-
Rhea-AI Summary

The FDA has approved an updated label for LUPKYNIS, a drug by Aurinia Pharmaceuticals (NASDAQ: AUPH), including long-term data from the AURORA Clinical Program, showing sustained complete renal response through three years. The label now indicates that monthly kidney function assessment is no longer required after the first year of treatment. The safety profile of LUPKYNIS remains unchanged and aligns with the AURORA clinical program's findings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none

FAQ

What is the current stock price of Aurinia Pharmace (AUPH)?

The current stock price of Aurinia Pharmace (AUPH) is $7.49 as of July 2, 2025.

What is the market cap of Aurinia Pharmace (AUPH)?

The market cap of Aurinia Pharmace (AUPH) is approximately 1.1B.
Aurinia Pharmace

Nasdaq:AUPH

AUPH Rankings

AUPH Stock Data

1.08B
121.41M
7.54%
45.29%
8.38%
Biotechnology
Pharmaceutical Preparations
Link
Canada
EDMONTON